Vanessa Leguy-Seguin
Overview
Explore the profile of Vanessa Leguy-Seguin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dybal E, Maillot F, Feillet F, Fouilhoux A, Astudillo L, Lavigne C, et al.
Mol Genet Metab
. 2025 Feb;
144(3):109044.
PMID: 39919675
Phenylketonuria (PKU) treatment requires a low-phenylalanine (Phe) diet limiting natural protein intake, using medical low-protein foods and Phe-free amino acids (AA) supplements along with micronutriments' supplies. Current recommendations suggest maintaining...
2.
Tchan M, Lehman A, van Dussen L, Langendonk J, Janssen M, Langeveld M, et al.
J Inherit Metab Dis
. 2025 Feb;
48(2):e70005.
PMID: 39912519
There are still few centres, which specialise in the care of adults with inborn errors of metabolism (IEM). All physicians who participated in the SSIEM adult metabolic physicians group paper...
3.
Brachet M, Charriere S, Douillard C, Feillet F, Fouilhoux A, Astudillo L, et al.
J Neurol
. 2024 Dec;
272(1):53.
PMID: 39666084
Background And Objective: Adult patients with early-treated phenylketonuria (AwET-PKU) may present some subtle neurocognitive deficits. The aim of the study was to investigate 1) neurocognitive functions in a large group...
4.
Papo M, Razanamahery J, Da Silva M, Helias-Rodzewicz Z, Potapenko V, Bota S, et al.
Haematologica
. 2024 May;
109(9):3048-3052.
PMID: 38779720
No abstract available.
5.
Mauhin W, Dzangue-Tchoupou G, Amelin D, Corneau A, Lamari F, Allenbach Y, et al.
J Inherit Metab Dis
. 2024 Apr;
47(4):818-833.
PMID: 38623626
Fabry disease (FD) is an X-linked disease characterized by an accumulation of glycosphingolipids, notably of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysoGb3) leading to renal failure, cardiomyopathy, and cerebral strokes. Inflammatory processes...
6.
Guilhem A, Ciudad M, Aubriot-Lorton M, Greigert H, Cladiere C, Leguy-Seguin V, et al.
Front Immunol
. 2023 Dec;
14:1321182.
PMID: 38143764
Hereditary hemorrhagic telangiectasia (HHT) is a rare inherited disease due to heterozygous loss-of-function mutations on the BMP9/10 pathway ( or mainly). HHT endothelial cells are prone to lose their quiescence,...
7.
Razanamahery J, Godot A, Leguy-Seguin V, Samson M, Audia S, Bonnotte B
Front Immunol
. 2023 Oct;
14:1260193.
PMID: 37809108
Histiocytoses encompass a wide spectrum of diseases, all characterized by tissue infiltration by CD68+ histiocytes. Most adult histiocytoses are considered clonal diseases because they highlight recurrent somatic mutations in the...
8.
Dupuis-Girod S, Riviere S, Lavigne C, Fargeton A, Gilbert-Dussardier B, Grobost V, et al.
J Intern Med
. 2023 Aug;
294(6):761-774.
PMID: 37592715
Background: Bevacizumab-a humanized monoclonal antibody-has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet been conducted. Methods: This study is a double-blind...
9.
Grobost V, Hammi S, Pereira B, Guilhem A, Duffau P, Seguier J, et al.
Thromb Res
. 2023 Jul;
229:107-113.
PMID: 37437516
Background: It is unclear whether hereditary hemorrhagic telangiectasia (HHT) patients can tolerate antithrombotic therapies (AT) including antiplatelet (AP) and/or anticoagulant (AC) agents. Objectives: Primary endpoint was tolerance to AT in...
10.
Savard P, Leguy-Seguin V, Chavy C, Genre-Volot F, Callegarin A, Amiral J, et al.
Int J Lab Hematol
. 2023 Jun;
45(6):969-971.
PMID: 37293692
No abstract available.